The weight-loss drug Wegovy lowers the risk of “adverse cardiovascular events” by 20%, according to data from a major trial shared by the drug’s maker Novo Nordisk.
The weight-loss drug Wegovy lowers the risk of “adverse cardiovascular events” by 20%, according to data from a major trial shared by the drug’s maker Novo Nordisk on Tuesday, causing the company’s shares to surge.... [+]press release
, Novo Nordisk said a weekly 2.4 milligram dose of semaglutide—the generic name for Wegovy, which is also sold under the name “Ozempic”—resulted in a 20% reduction in heart attacks and strokes. The trial measured data over a period of five years and involved 17,604 participants aged 45 or older who were either overweight or obese.
The trial also found that the 2.4 mg dosage was “safe and well-tolerated” in line with previous similar trials. The announcement of the trial results caused the drug maker’s Copenhagen-listed shares to surge by more than 16% on Tuesday, before settling at around 13.4% in the green during afternoon trading.Key Backgroundearlier this year due to their effectiveness in aiding weight loss. Despite the differing brand names, both use the same medication known as Semaglutide with slightly different dosages.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Lire la suite »
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Lire la suite »
Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares SurgeNovo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
Lire la suite »
Morgan Stanley predicts Eli Lilly shares to rally on Novo's obesity drug dataMorgan Stanley believes that the positive data on Novo Nordisk's obesity drug Wegovy will also benefit Eli Lilly, leading to a potential increase in its stock value. Novo Nordisk's shares surged by 15% following the release of late-stage trial data, which demonstrated that Wegovy reduced the risk of major cardiovascular events by 20% compared to a placebo.
Lire la suite »
Novo Nordisk hits record highs as study shows Wegovy treatment cut the risk of heart issues by 20%Shares of Novo Nordisk reached record highs after a study revealed that its Wegovy treatment reduced the risk of heart issues by 20%. The positive results have generated excitement among investors and healthcare professionals.
Lire la suite »
Wegovy Reduces Risk of Heart Attack and Stroke in Major Cardiovascular TrialA major clinical trial has shown that the weight loss drug Wegovy can reduce the risk of heart attack, stroke, or heart disease-related death by 20% in people with cardiovascular disease, marking the first time a weight loss drug has demonstrated such protective effects.
Lire la suite »